Clinical Trials Logo

Clinical Trial Summary

This study (FLOWER) will investigate effectiveness, safety, progression patterns and clinical management of untreated advanced NSCLC patients receiving fist-line osimertinib in the real-world.


Clinical Trial Description

FLOWER is a real-world, prospective, observational study enrolling patients with histological and/or cytological diagnosis of EGFR-mutant aNSCLC, receiving first-line treatment with the third-generation EGFR-TKI, osimertinib. All the patients received osimertinib at the recommended dose of 80 mg, orally, once a day. Dosing interruptions or reductions required, based on individual tolerability, were managed according to clinical practice in compliance with label indications. The FLOWER study aims at evaluating effectiveness, safety, progression pattern and clinical management of untreated EGFR-mutant aNSCLC patients in the real-world. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04965701
Study type Observational
Source Istituto Oncologico Veneto IRCCS
Contact
Status Completed
Phase
Start date June 1, 2018
Completion date May 31, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT04989322 - Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC Phase 2
Recruiting NCT03349203 - Icotinib as Neoadjuvant and Adjuvant Therapy in EGFR-mutant Stage IIIB or Oligometastasis Non-small Cell Lung Cancer Phase 2
Not yet recruiting NCT05998993 - Study to Evaluate SBRT for EGFR Mutant NSCLC Patients Receiving Osimertinib (CULTRO) N/A
Recruiting NCT05033691 - A Study to Evaluate the Efficacy of Osimertinib With Early Intervention SRS Treatment Compared to the Continuation of Osimertinib Alone, in Patients With EGFR Mutated NSCLC and Asymptomatic Brain Metastases N/A
Recruiting NCT05256290 - Phase 1/2 Study of BDTX-1535 in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations Phase 1/Phase 2
Withdrawn NCT04464967 - Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers Phase 1/Phase 2
Completed NCT04640870 - The Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients With Advanced EGFR Mutation-positive Non-small Cell Lung Cancer Treated With Afatinib
Active, not recruiting NCT04862780 - (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC Phase 1/Phase 2
Not yet recruiting NCT05110950 - Endobronchial Ultrasound Needle Aspiration With and Without Suction N/A
Recruiting NCT06352502 - An Observational Study of Furmonertinib for EGFR Mutation-positive NSCLC Patients With Brain Metastasis
Terminated NCT05153408 - (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC Phase 1
Not yet recruiting NCT05132985 - Neoadjuvant Icotinib With Chemotherapy for Epidermal Growth Factor Receptor(EGFR)-Mutated Resectable Lung Adenocarcinoma Phase 2
Recruiting NCT04504071 - Dacomitinib in Lung Cancer With Uncommon EGFR Mutations Phase 2
Recruiting NCT06109558 - The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC Phase 1/Phase 2
Recruiting NCT05165355 - Adjuvant Targeted-therapy for Patients With Resected High-risk EGFR-mutant Stage IB-IIA Non-small Cell Lung Carcinoma Phase 2
Recruiting NCT06207292 - Stereotactic Ablative Radiotherapy in Synchronous and Metachronous Oligo-Metastatic Non Small Cell Lung Cancer N/A
Recruiting NCT05573373 - Pamiparib (BGB-290) Was Used in EGFR-TkIs Resistant Non-small Cell Lung Cancer Phase 1
Recruiting NCT03749213 - Icotinib as Neoadjuvant Therapy in EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung Cancer Phase 2
Recruiting NCT05263947 - Bevacizumab Combined With Double Dose Icotinib in Patients With EGFR Exon 21-L858R Mutation Phase 2
Not yet recruiting NCT06287593 - The Feasibility of Dynamic Liquid Biopsy Monitoring During Neoadjuvant Treatment for EGFR-mutated NSCLC N/A